S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

$1.78
-0.01 (-0.56%)
(As of 03/28/2024 ET)
Today's Range
$1.76
$1.85
50-Day Range
$1.76
$2.36
52-Week Range
$0.66
$4.19
Volume
273,600 shs
Average Volume
218,734 shs
Market Capitalization
$87.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.63

Corvus Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
272.2% Upside
$6.63 Price Target
Short Interest
Bearish
4.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Corvus Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

656th out of 938 stocks

Pharmaceutical Preparations Industry

298th out of 426 stocks

CRVS stock logo

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

CRVS Stock Price History

CRVS Stock News Headlines

Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
Q4 2023 Corvus Pharmaceuticals Inc Earnings Call
Make This $3 Trade the Instant the Opening Bell Rings
Since the birth of Wall Street, one simple rule has remained the same.... Buy stocks that are cheap....When they’re on sale…. And when nobody else is looking…
CRVS Apr 2024 4.000 put
CRVS Mar 2024 3.000 put
Corvus Edges up on Disclosing Data
Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up
Corvus Pharmaceuticals Inc CRVS
See More Headlines
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2021
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRVS
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.63
High Stock Price Target
$12.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+272.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-27,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.79 per share

Miscellaneous

Free Float
33,690,000
Market Cap
$87.29 million
Optionable
Optionable
Beta
1.04
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Richard A. Miller M.D. (Age 73)
    Co-Founder, President, CEO & Chairman of the Board
    Comp: $306k
  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Director
    Comp: $47k
  • Mr. Leiv Lea (Age 70)
    Chief Financial Officer
    Comp: $388.73k
  • Dr. William Benton Jones Ph.D. (Age 58)
    Senior Vice President of Pharmaceutical Development
    Comp: $346.42k
  • Dr. James T. Rosenbaum M.D.
    Senior Vice President of Research
  • Mr. Jeffrey S. Arcara
    Chief Business Officer

CRVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Corvus Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRVS shares.
View CRVS analyst ratings
or view top-rated stocks.

What is Corvus Pharmaceuticals' stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Corvus Pharmaceuticals' shares. Their CRVS share price targets range from $3.50 to $12.00. On average, they predict the company's share price to reach $6.63 in the next twelve months. This suggests a possible upside of 272.2% from the stock's current price.
View analysts price targets for CRVS
or view top-rated stocks among Wall Street analysts.

How have CRVS shares performed in 2024?

Corvus Pharmaceuticals' stock was trading at $1.76 on January 1st, 2024. Since then, CRVS shares have increased by 1.1% and is now trading at $1.78.
View the best growth stocks for 2024 here
.

Are investors shorting Corvus Pharmaceuticals?

Corvus Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,490,000 shares, an increase of 17.3% from the February 29th total of 1,270,000 shares. Based on an average trading volume of 218,100 shares, the days-to-cover ratio is presently 6.8 days. Currently, 4.0% of the shares of the stock are sold short.
View Corvus Pharmaceuticals' Short Interest
.

When is Corvus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CRVS earnings forecast
.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) posted its quarterly earnings results on Sunday, October, 31st. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24).

What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO?

4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend.

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO).

When did Corvus Pharmaceuticals IPO?

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Towerview LLC (0.89%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones.
View institutional ownership trends
.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRVS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners